Skip to main content
EXEL logo

EXEL · Exelixis, Inc. · Webcasts, Transcripts & Audio

Track EXEL — free
Market Cap
$15.77B
Shares
244.01M
Volume · Nov 20 2.19M Avg daily vol (3M) 2.44M

Exelixis, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Exelixis, Inc. (EXEL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-18
Exelixis, Inc. (EXEL) November 18, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-17
Exelixis, Inc. (EXEL) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-11
Exelixis, Inc. (EXEL) November 11, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-11-10
Exelixis, Inc. (EXEL) November 10, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-10-29
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
Confident tone Cabo commercial growth ZANSA franchise expansion Colorectal cancer launch opportunity
Revenue
$658.70M
▲ 10.2% YoY
Diluted EPS
$0.85
▲ 23.2% YoY
Gross margin
96.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Exelixis, Inc. (EXEL) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Exelixis, Inc. (EXEL) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-08
Exelixis, Inc. (EXEL) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript
Positive tone NET indication ramp Cabozantinib (Cabo) commercial performance 2026 financial guidance revision
Revenue
$628.69M
▲ 10.6% YoY
Diluted EPS
$0.82
▲ 26.2% YoY
Gross margin
96.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-09
Exelixis, Inc. (EXEL) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Exelixis, Inc. (EXEL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-27
Exelixis, Inc. (EXEL) May 27, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-19
Exelixis, Inc. (EXEL) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
Exelixis, Inc. (EXEL) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
Confident tone ZANSA in renal cell carcinoma franchise Zanzalintinib (ZANSA) CRC launch and Stellar 303 ZANSA in neuroendocrine tumors and meningioma
Revenue
$610.81M
▲ 10% YoY
Diluted EPS
$0.79
▲ 43.6% YoY
Gross margin
96.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-10
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
Confident tone Zanzalintinib (ZANZA) franchise opportunity Cabozantinib (CABOMETYX) franchise performance Pipeline / R&D strategy
Revenue
$598.66M*
▲ 5.6% YoY
Gross margin
95.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript
Confident tone Zanzalintinib pipeline and STELLAR-303 CRC results NET indication launch CRC market dynamics and competition
Revenue
$597.75M
▲ 10.8% YoY
Diluted EPS
$0.69
▲ 72.5% YoY
Gross margin
96.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-28
Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript
Confident tone STELLAR-303 zanzalintinib in CRC Early-stage pipeline advancement Gross-to-net dynamics and 340B
Revenue
$568.26M
▼ 10.8% YoY
Diluted EPS
$0.65
▼ 15.6% YoY
Gross margin
96.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript
Confident tone CABOMETYX commercial performance NET launch Early-stage pipeline and INDs
Revenue
$555.45M
▲ 30.6% YoY
Diluted EPS
$0.55
▲ 358.3% YoY
Gross margin
96.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript
Confident tone Zanzalintinib pivotal trials Cabozantinib commercial performance STELLAR-303 colorectal cancer data and trial design
Revenue
$566.75M*
▲ 18.2% YoY
Gross margin
96.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript
Confident tone Cabozantinib (CABOMETYX) franchise performance Early-stage pipeline (XL309, XB010, XL495) Merck collaboration on Zanza
Revenue
$539.54M
▲ 14.3% YoY
Diluted EPS
$0.40
Gross margin
96.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript
Confident tone CABINET sNDA and neuroendocrine tumors (NET) launch Cabozantinib commercial performance and RCC leadership Discovery and IND-enabling programs
Revenue
$637.18M
▲ 35.6% YoY
Diluted EPS
$0.77
▲ 208% YoY
Gross margin
97.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript
Positive tone Zanzalintinib development Cabozantinib (CABOMETYX) commercial performance Early-stage pipeline / discovery
Revenue
$425.23M
▲ 4% YoY
Diluted EPS
$0.12
▲ 0% YoY
Gross margin
95.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript
Revenue
$479.65M*
▲ 13.1% YoY
Gross margin
95.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Exelixis, Inc. (EXEL) Q3 2023 Earnings Call Transcript
Revenue
$471.92M
▲ 14.6% YoY
Diluted EPS
$0.00
▼ 100% YoY
Gross margin
96.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Exelixis, Inc. (EXEL) Q2 2023 Earnings Call Transcript
Revenue
$469.85M
▲ 12% YoY
Diluted EPS
$0.25
▲ 13.6% YoY
Gross margin
96.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Exelixis, Inc. (EXEL) Q1 2023 Earnings Call Transcript
Revenue
$408.79M
▲ 14.8% YoY
Diluted EPS
$0.12
▼ 42.9% YoY
Gross margin
96.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2022 Earnings Call Transcript
Revenue
$423.92M*
▼ 6% YoY
Gross margin
96.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Exelixis, Inc. (EXEL) Q3 2022 Earnings Call Transcript
Revenue
$411.74M
▲ 25.4% YoY
Diluted EPS
$0.23
▲ 91.7% YoY
Gross margin
96.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Exelixis, Inc. (EXEL) Q2 2022 Earnings Call Transcript
Revenue
$419.43M
▲ 8.9% YoY
Diluted EPS
$0.22
▼ 26.7% YoY
Gross margin
96.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Exelixis, Inc. (EXEL) Q1 2022 Earnings Call Transcript
Revenue
$355.98M
▲ 31.7% YoY
Diluted EPS
$0.21
Gross margin
96.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2021 Earnings Call Transcript
Revenue
$451.14M*
▲ 67.1% YoY
Gross margin
97.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Exelixis, Inc. (EXEL) Q3 2021 Earnings Call Transcript
Revenue
$328.42M
▲ 42.1% YoY
Diluted EPS
$0.12
Gross margin
96.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Exelixis, Inc. (EXEL) Q2 2021 Earnings Call Transcript
Revenue
$385.18M
▲ 48.4% YoY
Diluted EPS
$0.30
▲ 42.9% YoY
Gross margin
96.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Exelixis, Inc. (EXEL) Q1 2021 Earnings Call Transcript
Revenue
$270.23M
▲ 19.1% YoY
Diluted EPS
$0.00
▼ 100% YoY
Gross margin
95.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2020 Earnings Call Transcript
Revenue
$270.05M
▲ 12.4% YoY
Diluted EPS
$0.09
▼ 59.1% YoY
Gross margin
70.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Exelixis, Inc. (EXEL) Q3 2020 Earnings Call Transcript
Revenue
$231.09M
▼ 14.9% YoY
Diluted EPS
$-0.10
▼ 132.3% YoY
Gross margin
69.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Exelixis, Inc. (EXEL) Q2 2020 Earnings Call Transcript
Revenue
$259.48M
▲ 8% YoY
Diluted EPS
$0.21
▼ 16% YoY
Gross margin
65.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Exelixis, Inc. (EXEL) Q1 2020 Earnings Call Transcript
Revenue
$226.91M
▲ 5.3% YoY
Diluted EPS
$0.15
▼ 37.5% YoY
Gross margin
81.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–39 of 39 webcasts
Key facts CIK 939767 CUSIP 30161Q104 13F (30d) 716 filings 661 filers Visit website Investor relations